Among PARP Inhibitors, Researchers Identify Least Costly to Payers

December 11, 2018

A US cost comparison of poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors used to treat women with ovarian cancer found niraparib to have the lowest monthly cost for payers, according to a study in the Journal of Managed Care & Specialty Pharmacy.

The retrospective study compared the monthly drug cost of niraparib, olaparib (tablets and capsules), and rucaparib. Researchers used the IBM Watson Health commercial and Medicare databases to identify women diagnosed with ovarian cancer between January 2017 and February 2018.

The study included 335 women: 155 received niraparib, 50 received the tablet form of olaparib, 61 received the capsule form of olaparib, and 69 received rucaparib.

The mean cost per month to payers was $11,729 for niraparib, researchers reported. At $13,392 per month, rucaparib cost payers 14% more per month than niraparib.

The study also found the mean monthly cost to payers for olaparib tablets ($14,382) was 33% higher than the cost of olaparib capsules ($10,809). Compared with the mean monthly cost of niraparib, olaparib tablets were 23% more expensive. 

“Cost per month to payers among PARP inhibitors was lowest for niraparib,” researchers concluded. “There was an increase in monthly cost after the olaparib formulation was switched from capsule to tablet.”

The study, which was sponsored by drugmaker Tesaro, was presented at AMCP Nexus 2018.

Jolynn Tumolo


Louie-Gao M, Song X, Harrow B. Cost comparison of PARP inhibitors in women with ovarian cancer in the U.S. Journal of Managed Care & Specialty Pharmacy. 2018;24(10-a):S26.

For articles by First Report Managed Care, click here

To view the First Report Managed Care print issue, click here